Risankizumab outperforms placebo at 6 months for psoriatic arthritisNovember 8, 2021Psoriatic Arthritis
Effect of background methotrexate dose on tofacitinib efficacy in patients with PsAOctober 24, 2021Psoriatic Arthritis
Predictors and risk factors for PsA transition in patients with psoriasisOctober 24, 2021Psoriatic Arthritis
Itch relief major contributor for tofacitinib-mediated–improved QoL in PsAOctober 24, 2021Psoriatic Arthritis
PsA: Long-term apremilast offers clinical benefits in ACR20 nonrespondersOctober 24, 2021Psoriatic Arthritis
Psoriasis patients with more severe disease at higher risk of developing PsAOctober 24, 2021Psoriatic Arthritis
Study identifies different patient priorities when selecting biologics for PsAOctober 24, 2021Psoriatic Arthritis
PsA: Phase 3 confirms rapid and significant response of secukinumab on synovitisOctober 24, 2021Psoriatic Arthritis
Psoriasis patients initiating biologics more likely to develop PsAOctober 24, 2021Psoriatic Arthritis
Disease activity-guided dose optimization of TNF inhibitors safe and effective in PsAOctober 24, 2021Psoriatic Arthritis
Tramadol linked to higher risk of mortality, compared with codeineOctober 19, 2021Psoriatic Arthritis
U.S. arthritis prevalence continues steady rise; activity limitations grow more rapidlyOctober 18, 2021Psoriatic Arthritis
